Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Aims To Turn Brintellix Into CNS Cornerstone, Arm-In-Arm With Lundbeck

Executive Summary

Multimodal antidepressant Brintellix (vortioxetine) represents Takeda’s first shot at a major depression launch and the future for Lundbeck as blockbuster Lexapro fades into the distance. Time will tell if the partners have what it takes to compete in a highly genericized market; evidence of cognitive benefits could help.

Advertisement

Related Content

IQWIG Finds No Added Benefit With Novo’s Xultophy Or Lundbeck’s Brintellix
Brintellix Label Gives Lundbeck Ground For Tolerability Claims
Takeda’s Tachi Yamada Discusses The Late-Stage Pipeline: An Interview At PSA 2013
APA Update: New Antidepressants Elbow Into Crowded Market

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS055659

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel